Do you have non-segmental vitiligo?

A clinical trial to assess a new drug for non-segmental vitiligo

Vitiligo is a chronic skin disorder characterised by a patchy loss of skin colour. This loss of skin colour could be focused in one area of the body for some patients (called “segmental vitiligo”) or could be dispersed over various areas of the body for other patients (called “non‑segmental vitiligo”). In human beings, melanin, a biological molecule, is responsible for skin colour and is called the skin pigment. Melanin is produced by certain types of cells in the body called melanocytes. In vitiligo, the skin loses these melanocytes due to complex reactions involving many different biological molecules.

PF‑06651600 and PF‑06700841 are study drugs and are being developed as possible treatments for patients with non‑segmental and active vitiligo.

The study drugs act by blocking the activity of some of the biological molecules responsible for the loss of melanocytes. This project will explore whether the study drugs are effective in controlling vitiligo and if they are safe for human-use.

Enrolment status: Open for recruitment

Who can take part

Inclusion Criteria

  • Age 18 -64
  • Clinical diagnosis of non-segmental vitiligo for at least 3 months

Exclusion Criteria

  • History of severe psychiatric condition
  • Other types of vitiligo
  • Other active forms of inflammatory skin disease
  • Use of permanent depigmentation treatment

What is involved for you

  • Screening period (4 weeks), Dose Ranging period (24 weeks) +/- Extension period (24 weeks), Follow up period (8 weeks)
  • Blood/urine samples
  • chest x-ray
  • weight
  • blood pressure
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2019.018
Annette Phemister
03 9342 4531